Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 17 of 17

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2025

Dosing Methods, Instructions for Use, and Safety Data Outcomes from a Phase 3 Study Evaluating the Efficacy and Safety of AZR-MD-001 0.5% for the Treatment of MGD and DED

David Wirta; Lyndon Jones; Christopher E. Starr; Preeya Gupta; Sumit Garg; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):5676.

ARVO Annual Meeting Abstract June 2025

Characteristics of Participants with Mild to Moderate MGD Utilizing AZR-MD-001 0.5% in a Randomized, Placebo-Controlled, Phase 3 Trial

Kelly Nichols; Francis Mah; David Wirta; Preeya Gupta; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):5675.

ARVO Annual Meeting Abstract June 2024

AZR-MD-001 Efficacy in Resolving the Signs and Associated Symptoms of Contact Lens Discomfort in a Phase 2 Trial

Mark Hinds; Fiona Stapleton; Jacqueline Tan; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2971.

ARVO Annual Meeting Abstract June 2024

AZR-MD-001 Opens Meibomian Glands, Improves Meibum and Tear Quality Resulting in Increased Wear Time and Desired Lens Use in Patients With CLD

Lyndon Jones; Julie Schallhorn; Fiona Stapleton; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2677.

ARVO Annual Meeting Abstract June 2024

AZR-MD-001 Improved Corneal and Conjunctival Damage in Patients with CLD and MGD

Charles Bosworth; Mark Hinds; Eric G Kassel; Yair Alster

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2669.

ARVO Annual Meeting Abstract June 2024

Validity of the Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) and its comprehensiveness in assessing disease impact after the widespread adoption of digital media in patients with Contact Lens Discomfort (CLD) and concomitant Meibomian Gland Dysfunction (MGD)

Robin Chalmers; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5751.

ARVO Annual Meeting Abstract June 2024

AZR-MD-001 Ophthalmic Ointment Opens Meibomian Glands, Improves Meibum Quality, and Tear Film Stability Over 3 Months of Dosing in Patients with Contact Lens Discomfort

Fiona Stapleton; Jacqueline Tan; Mark Hinds; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6584.

ARVO Annual Meeting Abstract June 2024

AZR-MD-001 Improved Tear Film Stability and Ocular Symptoms in Patients with Meibomian Gland Dysfunction: 6-Month Results

Joshua C Teichman; Mark Hinds; Laura Elizabeth Downie; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6583.

ARVO Annual Meeting Abstract June 2024

Sign and Symptom Improvement Rates Among MGD Patients Following Treatment With AZRMD001 for 6 Months

Julie Marie Schallhorn; Lyndon Jones; Alison Ng; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6582.

ARVO Annual Meeting Abstract June 2024

Safety and Efficacy of Topical AZR-MD-001 for the Treatment of Meibomian Gland Dysfunction in a 6-Month Study

Jacqueline Tan; Fiona Stapleton; Laura Elizabeth Downie; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6578.

ARVO Annual Meeting Abstract June 2023

AZR-MD-001 efficacy in improving tear film stability and its impact on associated symptoms of meibomian gland dysfunction in a Phase 2 trial

Fiona Stapleton; Jacqueline Tan; Lyndon William Jones; Alison Ng; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4011.

ARVO Annual Meeting Abstract June 2023

AZR-MD-001 restores gland gunction and improves signs and ocular symptoms of mebomian gland dysfunction (MGD)

Preeya Gupta; Laura Elizabeth Downie; Mark Hinds; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):5175.

ARVO Annual Meeting Abstract June 2023

AZR-MD-001 efficacy in resolving the signs and associated symptoms of meibomian gland dysfunction (MGD) in a phase 2 trial: responder status analysis

Lisa Nijm; Jennifer P Craig; Mark Hinds; Yair Alster; Charles Bosworth

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):5129.

ARVO Annual Meeting Abstract June 2023

Nonclinical assessment of repeated dosing of AZR-MD-001 to the lower eyelid (Selenium Sulphide, SeS 2 , sterile ophthalmic ointment): A novel therapy being developed for meibomian gland dysfunction

Limor Miara; Glenwood G Gum; Luba Litinetsky; Kathleen Krenzer; Linda Manza; Charles Bosworth; Yair Alster; Hila Epstin-Barash

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):172.

ARVO Annual Meeting Abstract June 2021

Lipogenic activity of Selenium Disulfide and its role in enhancing lipid production in Meibomian Glands

Yair Alster; Hila Epstein-Barash; Hadas Rapaport; Omer Rafaeli

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):693.

ARVO Annual Meeting Abstract June 2021

Keratolytic and Keratostatic activity of Selenium Disulfide and its disease modifying role in Meibomian Gland Disease

Hila Epstein-Barash; Hadas Rapaport; Yair Alster; Omer Rafaeli

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):692.

ARVO Annual Meeting Abstract June 2020

Phase 1 Clinical Study of the Port Delivery System with ranibizumab for continuous treatment of neovascular age-related macular degeneration

Anat Loewenstein; Guna Laganovska; Neil M Bressler; Juris Vanags; Yair Alster; Eugene De Juan; Jay M Stewart; David Kardatzke; Natasha Singh; Signe Erickson

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4201.

Advertisement